posted on 2023-08-25, 05:42authored byAyeshah A Rosdah, Belinda M Abbott, Christopher G Langendorf, Yali Deng, Jia Q Truong, Helen MM Waddell, Naomi XY Ling, William J Smiles, Lea MD Delbridge, Guei-Sheung LiuGuei-Sheung Liu, Jonathan S Oakhill, Shiang Y Lim, Jessica K Holien
Mitochondrial dynamin-related protein 1 (Drp1) is a large GTPase regulator of mitochondrial dynamics and is known to play an important role in numerous pathophysiological processes. Despite being the most widely used Drp1 inhibitor, the specificity of Mdivi-1 towards human Drp1 has not been definitively proven and there have been numerous issues reported with its use including off-target effects. In our hands Mdivi-1 showed varying binding affinities toward human Drp1, potentially impacted by compound aggregation. Herein, we sought to identify a novel small molecule inhibitor of Drp1. From an initial virtual screening, we identified DRP1i27 as a compound which directly bound to the human isoform 3 of Drp1 via surface plasmon resonance and microscale thermophoresis. Importantly, DRP1i27 was found to have a dose-dependent increase in the cellular networks of fused mitochondria but had no effect in Drp1 knock-out cells. Further analogues of this compound were identified and screened, though none displayed greater affinity to human Drp1 isoform 3 than DRP1i27. To date, this is the first small molecule inhibitor shown to directly bind to human Drp1.
History
Sub-type
Article
Publication title
Scientific Reports
Medium
Electronic
Volume
12
Issue
1
Article number
21531
Pagination
13
eISSN
2045-2322
ISSN
2045-2322
Department/School
Menzies Institute for Medical Research, UTAS Centre for Rural Health
Publisher
NATURE PORTFOLIO
Publication status
Published
Place of publication
England
Event Venue
St Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.